All In Biotech

Drug Trial Radar · NCT05470608

Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Escalation Study to Assess the Safety and Efficacy of SL-1002 Injectable for Treatment of Knee Pain Associated With Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Aug 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

132

Planned (sponsor's estimate)

Start

Jun 13, 2022

Primary completion

Jan 2024

Study completion Jan 2024

Sponsor

Lead sponsor
Saol Therapeutics IncIndustry
Sponsor type
Industry
First posted
Jul 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, single ascending dose escalation study to assess the safety and efficacy of single treatment exposure of an injectable formulation of SL-1002 for the treatment of knee pain associated with osteoarthritis. Phase A of the study will enroll 3 cohorts of 8 patients per cohort, for a total of 24 patients. Patients will be randomized to receive either SL-1002 or placebo in a 3:1 ratio within each given cohort. Phase B of the study will enroll a minimum of 92 up to a maximum of 108 patients. Patients will be randomized to receive either SL-1002 or placebo in a 3:1 ratio at the recommended dose determined from Phase A. The study period will be up to 168 days inclusive of a screening period of up to 28 days.

Conditions

  • Osteoarthritis, Knee Pain

Interventions

  • SL-1002Drug

    SL-1002 injectable solution

  • PlaceboDrug

    Matching placebo injectable solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of treatment emergent adverse events (TEAEs) overallTime frame: Time of study drug administration to end of study visit (day 168)
  2. Improvement of knee painTime frame: Change from baseline to Month 3 in 11 point NRS score

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Denver Spine & Pain Institute

    Greenwood Village, Colorado

  • International Spine, Pain & Performance Center

    Washington D.C., District of Columbia

  • Prime Medical Research

    Coral Gables, Florida

  • Conquest Research

    Winter Park, Florida

  • Northwestern University

    Chicago, Illinois

  • Mayo Clinic

    Rochester, Minnesota

  • Cooper Neurological Institute

    Camden, New Jersey

  • Center for Clinical Research

    Winston-Salem, North Carolina

  • Pacific Sports and Spine

    Eugene, Oregon

  • University Orthopedics Center

    Altoona, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Institute of Precision Pain Medicine

    Corpus Christi, Texas

  • Precision Spine Care

    Tyler, Texas

  • University of Utah School of Medicine

    Salt Lake City, Utah

  • Virginia iSpine Physicians

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.